tiprankstipranks

CG Oncology assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of CG Oncology (CGON) with an Overweight rating and $55 price target Morgan Stanley sees a competitive profile for cretostimogene in bladder cancer, with indication expansion potential beyond high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. In addition to strong data, the firm thinks the familiarity of the same route of administration as standard-of-care BCG therapy should help encourage urologists to prescribe cretostimogene once approved.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue